Download PDF
Thromb Haemost 1996; 76(06): 0989-0992
DOI: 10.1055/s-0038-1650697
Original Article
Schattauer GmbH Stuttgart

The Antithrombotic Potential of Dalteparin in Man Assessed Indirectly by Wessler’s Technique

J Millet
Laboratoires Fournier SCA, Daix, France
,
J Theveniaux
Laboratoires Fournier SCA, Daix, France
,
G Tachon
Laboratoires Fournier SCA, Daix, France
,
Y Bogaievsky
Laboratoires Fournier SCA, Daix, France
,
J C Grippat
1   Pragmapharm, Paris, France
,
M Samama
2   Service d’Hématologie Biologique, Hôtel-Dieu, Paris, France
,
N L Brown
Laboratoires Fournier SCA, Daix, France
› Author Affiliations
Further Information

Publication History

Received 20 May 1996

Accepted after resubmission 21 August 1996

Publication Date:
21 August 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

The aim of this study was to demonstrate the effectiveness of a new experimental approach for assessing the antithrombotic potential of low molecular weight heparins (LMWH) such as dalteparin. In this approach, sera obtained from healthy volunteers treated with various i.v. doses of dalteparin (30, 60 or 120 anti-Xa IU/kg) or placebo (physiological saline) were used as the thrombogenic challenge in a Wessler’s stasis model of experimental venous thrombosis in the rat. Sera from placebo-treated volunteers showed a stable thrombogenic activity (0.25 ml/kg of serum producing thrombi of about 50 mg wet weight). Sera from healthy volunteers having previously received dalteparin however demonstrated dose- and time-related reductions in their thrombogenic activity. Half-lives of these effects were 300, 444 and >480 min for 30,60 and 120 anti-Xa IU/kg dalteparin respectively. These values were significantly higher than the corresponding anti-Xa and anti-IIa half-lives.

 

  • References

  • 1 Harenberg J. Relation of antifactor Xa activity of heparins and antithrombotic efficacity. Haemostasis 1988; 18 (Suppl. 03) 16-19
    PubMedSearch in Google Scholar
  • 2 Ofosu FA, Blajchman MA, Modi GJ, Smith LM, Buchanan MR, Hirsh J. The importance of thrombin inhibition for the expression of anticoagulant activities of heparin, dermatan sulphate, low molecular weight heparin and pentosan polysulfate. Br J Haematol 1985; 60: 695-704
    CrossrefPubMedSearch in Google Scholar
  • 3 Pieters J, Lindhout T. The limited importance of factor Xa inhibition to the anticoagulant property of heparin in thromboplastin-activated plasma. Blood 1988; 72: 2048-2052
    PubMedSearch in Google Scholar
  • 4 Walenga JM, Bara L, Petitout M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988; 51: 23-33
    CrossrefPubMedSearch in Google Scholar
  • 5 Barrowcliffe TW, Merton RE, Havercroft SJ, Lindahl U, Thomas DP. Low affinity heparin potentiates the action of high affinity heparin oligosaccharides. Thromb Res 1984; 34: 125-134
    CrossrefPubMedSearch in Google Scholar
  • 6 Tew CJ, Lane DA, Thompson E, Ireland H, Curtis JR. Relationship between ex vivo anti-protease (factor Xa and thrombin) assays and in vivo anticoagulant effect of very low molecular weight heparin, CY 222. Brit J Haematol 1988; 70: 335-340
    CrossrefPubMedSearch in Google Scholar
  • 7 Wessler S, Morris LE. Studies on intravascular coagulation. IV. The effect of heparin and Dicoumarol on serum-induced venous thrombosis. Circulation 1955; 12: 553-556
    PubMedSearch in Google Scholar
  • 8 Fareed J, Walenga JM, Kumar A, Rock A. A modified stasis thrombosis model to study the antithrombotic actions of heparin and its fractions. Semin Thromb Hemost 1985; 11: 155-175
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-198
    CrossrefPubMedSearch in Google Scholar
  • 10 Van Ryn-McKenna J, Gray E, Ofosu FA, Buchanan MR. Effects of sulfated polysaccharides on inhibition of thrombus formation initiated by different stimuli. Thromb Haemost 1989; 61: 7-9
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Millet J, Vaillot M, Theveniaux J, Brown NL. Experimental venous thrombosis induced by homologous serum in the rat. Thromb Res 1996; 81: 497-502
    CrossrefPubMedSearch in Google Scholar
  • 12 Millet J, Theveniaux J, Brown NL. The venous antithrombotic effect of LF 1351 in the rat following oral administration. Thromb Haemost 1992; 67: 176-179
    Thieme ConnectPubMedSearch in Google Scholar
  • 13 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosis inducing activity in human serum. J Appl Physiol 1959; 14: 943-946
    CrossrefPubMedSearch in Google Scholar
  • 14 Hemker HC, Willems GM, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17
    Thieme ConnectPubMedSearch in Google Scholar
  • 15 Jesty J. Analysis of the generation and inhibition of activated coagulation factor X pure systems and in human plasma. J Biol Chem 1986; 261: 8695-8702
    PubMedSearch in Google Scholar
  • 16 Sandset M, Abilgaard U. Extrinsic pathway inhibitor. The key of feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-239
    PubMedSearch in Google Scholar
  • 17 Bara L, Bloch MF, Zittoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier A. Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993; 69: 443-452
    CrossrefPubMedSearch in Google Scholar
  • 18 Hauptmann J, Kaiser B. Anticoagulant potential of synthetic and recombinant inhibitors of factor Xa and thrombin in vitro. Blood Coag Fibrin 1993; 4: 577-582
    CrossrefPubMedSearch in Google Scholar
  • 19 Buchanan MR, Boneu B, Hirsh J. The relative importance of thrombin inhibition and factor Xa inhibition to antithrombotic effects of heparin. Blood 1985; 65: 198-201
    PubMedSearch in Google Scholar
  • 20 Thomas DP, Merton RE, Barrowcliffe TW, Thunberg L, Lindahl U. Effects of heparin oligosaccharides with affinity for antithrombin III in experimental venous thrombosis. Thromb Haemost 1982; 47: 244-248
    Thieme ConnectPubMedSearch in Google Scholar
  • 21 Breddin HK. Low molecular weight heparins’ state-of-the-art and unsolved issues. Blood Coag Fibrin 1993; 4: S17-S19
    PubMedSearch in Google Scholar
  • 22 Monreal M, Silveira P, Monreal L, Monasterio J, Angles AM, Lafoz E, Lorente L. Comparative study on the antithrombotic efficacy of four low molecular weight heparins in three different models of experimental venous thrombosis. Haemostasis 1991; 21: 91-97
    PubMedSearch in Google Scholar
  • 23 Mattsson CH, Palm M, Soderberg K, Holmer E. Antithrombotic effects of heparin oligosaccharides. In: Heparin and related polysaccharides. Structure and activities Ofosu FA, Danishefsky I, Hirsh J. eds Ann New York Acad Sci. 1989. 556 323-332
  • 24 Dawes J, Bara L, Billaud E, Samama M. Relationship between biological activity and concentration of a low-molecular-weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Haemostasis 1986; 16: 116-122
    PubMedSearch in Google Scholar
  • 25 Frydman AM, Bara L, Le Roux Y, Woler M, Chauliac F, Samama M. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988; 28: 609-618
    CrossrefPubMedSearch in Google Scholar
  • 26 Briant L, Caranobe C, Saivin S, Sié P, Bayrou B, Houin G, Boneu B. Unfractionated heparin and CY 216: pharmacokinetics and bioavalabilities of the antifactor Xa and Ha effects after intravenous and subcutaneous injection in the rabbit. Thromb Haemost 1989; 61: 348-353
    Thieme ConnectPubMedSearch in Google Scholar
  • 27 Ofosu FA. Pharmacology of unfractionated and low molecular weight heparins. In Low molecular weight heparins in prophylaxis and therapy of thromboembolic diseases Golhaber SZ, Bounameaux H. eds 1994: 1-20
  • 28 Barbanti M, Calanni F, Milani MR, Marchi E, Semeraro N, Colucci M. Therapeutic effect of a low molecular weight dermatan sulphate (Desmin 370) in rat venous thrombosis evidence for an anticoagulant independent mechanism. Thromb Haemost 1993; 69: 147-151
    Thieme ConnectPubMedSearch in Google Scholar
  • 29 Doutremepuich C, Llida S, Lalanne MC, Doutremepuich F. Modifications of biological activities of heparin and fraxiparine induced by the size and the age of a thrombus. Experimental study. Thromb Res 1990; 59: 439-447
    PubMedSearch in Google Scholar